Abstract
Summary
Vitamin K may affect bone mineral density and fracture incidence. Since publication of a previous systematic review the integrity of some of the previous evidence has been questioned and further trials have been published. Therefore an update to the systematic review was required.
Introduction
This systematic review was designed to assess the effectiveness of oral vitamin K supplementation for increasing bone mineral density and reducing fractures in adults.
Methods
MEDLINE, EMBASE, CENTRAL, CINAHL, clinicaltrials.gov, and WHO-ICTRP were searched for eligible trials. Randomised controlled trials assessing oral vitamin K supplementation that assessed bone mineral density or fractures in adult populations were included. A total of 36 studies were identified. Two independent reviewers extracted data using a piloted extraction form.
Results
For post-menopausal or osteoporotic patients, meta-analysis showed that the odds of any clinical fracture were lower for vitamin K compared to controls (OR, 0.72, 95%CI 0.55 to 0.95). Restricting the analysis to low risk of bias trials reduced the OR to 0.76 (95%CI, 0.58 to 1.01). There was no difference in vertebral fractures between the groups (OR 0.96, 95%CI 0.83 to 1.11). In the bone mineral density meta-analysis, percentage change from baseline at the lumbar spine was higher at 1 year (MD 0.93, 95%, CI − 0.02 to 1.89) and 2 years (MD 1.63%, 95%CI 0.10 to 3.16) for vitamin K compared to controls; however, removing trials at high risk of bias tended to result in smaller differences that were not statistically significant. At 6 months, it was higher in the hip (MD 0.42%, 95%CI 0.01 to 0.83) and femur (MD 0.29%, 95%CI 0.17 to 0.42). There was no significant difference at other anatomical sites.
Conclusions
For post-menopausal or osteoporotic patients, there is no evidence that vitamin K affects bone mineral density or vertebral fractures; it may reduce clinical fractures; however, the evidence is insufficient to confirm this. There are too few trials to draw conclusions for other patient groups.
Similar content being viewed by others
Change history
23 September 2020
Following the work of Avenell et al. that has raised concerns about the integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) conducted by Ishida and Kawai we issue here an adjustment to all meta-analysis estimates that contained this work within our systematic review.
References
Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166(12):1256–1261. https://doi.org/10.1001/archinte.166.12.1256
Torgerson DJ (2018) Caution to readers about systematic review on vitamin K and prevention of fractures that included problematic trials. JAMA Intern Med 178(6):863–864. https://doi.org/10.1001/jamainternmed.2018.1127
Bolland MJ, Avenell A, Gamble GD, Grey A (2016) Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology 87(23):2391–2402. https://doi.org/10.1212/WNL.0000000000003387
Sato Y, Honda Y, Iwamoto J (2018) RETRACTED: etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized controlled trial. Bone 106:214. https://doi.org/10.1016/j.bone.2017.10.008
Booth SL (2009) Roles for vitamin K beyond coagulation. Annu Rev Nutr 29:89–110. https://doi.org/10.1146/annurev-nutr-080508-141217
Bügel S (2008) Vitamin K and bone health in adult humans. 78:393–416. https://doi.org/10.1016/s0083-6729(07)00016-7
Gundberg CM, Lian JB, Booth SL (2012) Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr 3(2):149–157. https://doi.org/10.3945/an.112.001834
Liu G, Peacock M (1998) Age-related changes in serum undercarboxylated osteocalcin and its relationships with bone density, bone quality, and hip fracture. Calcif Tissue Int 62(4):286–289. https://doi.org/10.1007/s002239900432
Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1993) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 91(4):1769–1774. https://doi.org/10.1172/JCI116387
Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD (1994) Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 9(10):1591–1595. https://doi.org/10.1002/jbmr.5650091012
Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J Clin Endocrinol Metab 82(3):719–724. https://doi.org/10.1210/jcem.82.3.3805
Booth SL, Broe KE, Peterson JW, Cheng DM, Dawson-Hughes B, Gundberg CM, Cupples LA, Wilson PW, Kiel DP (2004) Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab 89(10):4904–4909. https://doi.org/10.1210/jc.2003-031673
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Bmj 312(7041):1254–1259. https://doi.org/10.1136/bmj.312.7041.1254
Hao G, Zhang B, Gu M, Chen C, Zhang Q, Zhang G, Cao X (2017) Vitamin K intake and the risk of fractures: a meta-analysis. Medicine (Baltimore) 96(17):e6725. https://doi.org/10.1097/MD.0000000000006725
Garner P, Hopewell S, Chandler J, MacLehose H, Schunemann HJ, Akl EA, Beyene J, Chang S, Churchill R, Dearness K, Guyatt G, Lefebvre C, Liles B, Marshall R, Martinez Garcia L, Mavergames C, Nasser M, Qaseem A, Sampson M, Soares-Weiser K, Takwoingi Y, Thabane L, Trivella M, Tugwell P, Welsh E, Wilson EC, Schunemann HJ, Panel for updating guidance for systematic r (2016) When and how to update systematic reviews: consensus and checklist. BMJ 354:i3507. https://doi.org/10.1136/bmj.i3507
RETRACTION: risedronate therapy for prevention of hip fracture after stroke in elderly women; risedronate therapy for prevention of hip fracture after stroke in elderly women. Reply from the Authors (2016). Neurology 87 (2):239. https://doi.org/10.1212/WNL.0000000000002788
Kupferschmidt K (2018) Researcher at the center of an epic fraud remains an enigma to those who exposed him. Science. https://doi.org/10.1126/science.aav1079
Poisot T (2011) The digitize package: extracting numerical data from scatterplots. R J 3(1):25–26
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928
Hicks A, Fairhurst C, Torgerson DJ (2018) A simple technique investigating baseline heterogeneity helped to eliminate potential bias in meta-analyses. J Clin Epidemiol 95:55–62. https://doi.org/10.1016/j.jclinepi.2017.10.001
Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions, vol 5.1.0. https://doi.org/10.1002/9780470712184
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343:d4002. https://doi.org/10.1136/bmj.d4002
Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3). https://doi.org/10.18637/jss.v036.i03
R Development Core Team (2017) R: a language and environment for statistical computing. 3.4.0 edn. R Foundation for Statistical Computing, Vienna
Booth SL, Dallal G, Shea MK, Gundberg C, Peterson JW, Dawson-Hughes B (2008) Effect of vitamin K supplementation on bone loss in elderly men and women. J Clin Endocrinol Metab 93(4):1217–1223. https://doi.org/10.1210/jc.2007-2490
Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, Prynne CJ, Mishra GD, Shearer MJ (2007) Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res 22(4):509–519. https://doi.org/10.1359/jbmr.070116
Binkley N, Harke J, Krueger D, Engelke J, Vallarta-Ast N, Gemar D, Checovich M, Chappell R, Suttie J (2009) Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res 24(6):983–991. https://doi.org/10.1359/jbmr.081254
Braam LA, Knapen MH, Geusens P, Brouns F, Vermeer C (2003) Factors affecting bone loss in female endurance athletes: a two-year follow-up study. Am J Sports Med 31(6):889–895. https://doi.org/10.1177/03635465030310062601
Braam LAJLM, Knapen MHJ, Geusens P, Brouns F, Hamulyk K, Gerichhausen MJW, Vermeer C (2003) Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int 73(1):21–26. https://doi.org/10.1007/s00223-002-2084-4
Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R (2008) Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial. PLoS Med 5(10):e196. https://doi.org/10.1371/journal.pmed.0050196
Emaus N, Gjesdal CG, Almas B, Christensen M, Grimsgaard AS, Berntsen GK, Salomonsen L, Fonnebo V (2010) Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporos Int 21(10):1731–1740. https://doi.org/10.1007/s00198-009-1126-4
Forli L, Bollerslev J, Simonsen S, Isaksen GA, Kvamsdal KE, Godang K, Gadeholt G, Pripp AH, Bjortuft O (2010) Dietary vitamin K2 supplement improves bone status after lung and heart transplantation. Transplantation 89(4):458–464. https://doi.org/10.1097/TP.0b013e3181c46b69
Fulton RL, McMurdo ME, Hill A, Abboud RJ, Arnold GP, Struthers AD, Khan F, Vermeer C, Knapen MH, Drummen NE, Witham MD (2016) Effect of vitamin K on vascular health and physical function in older people with vascular disease—a randomised controlled trial. J Nutr Health Aging 20(3):325–333. https://doi.org/10.1007/s12603-015-0619-4
Gleeson D, Hodges S, Rigney E, Blumsohn A, Hannon R, Peel N, Eastell R (2003) 740 placebo-controlled trial of vitamin K supplementation on bone mineral density in primary biliary cirrhosis (PBC). Hepatology 38:516–516. https://doi.org/10.1016/s0270-9139(03)80782-6
Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 26(3):260–264. https://doi.org/10.1007/s00774-007-0823-3
Hozuki T, Imai T, Tsuda E, Matsumura A, Yamamoto D, Toyoshima T, Suzuki S, Yamauchi R, Hayashi T, Hisahara S, Shimohama S (2010) Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K2 in corticosteroid-treated patients: a pilot study. Intern Med 49(5):371–376. https://doi.org/10.2169/internalmedicine.49.2551
Inoue K, Hamano T, Nango N, Matsui I, Tomida K, Mikami S, Fujii N, Nakano C, Obi Y, Shimomura A, Kusunoki Y, Rakugi H, Isaka Y, Tsubakihara Y (2014) Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis. J Bone Miner Metab 32(3):271–280. https://doi.org/10.1007/s00774-013-0485-2
Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, Sato T, Yamazaki K (2009) Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab 27(1):66–75. https://doi.org/10.1007/s00774-008-0008-8
Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med 117(8):549–555. https://doi.org/10.1016/j.amjmed.2004.05.019
Iwamoto I, Kosha S, Noguchi S-i, Murakami M, Fujino T, Douchi T, Nagata Y (1999) A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen–progestin therapy. Maturitas 31(2):161–164. https://doi.org/10.1016/s0378-5122(98)00114-5
Je SH, Joo NS, Choi BH, Kim KM, Kim BT, Park SB, Cho DY, Kim KN, Lee DJ (2011) Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old. J Korean Med Sci 26(8):1093–1098. https://doi.org/10.3346/jkms.2011.26.8.1093
Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW (2014) Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin Interv Aging 9:121–127. https://doi.org/10.2147/CIA.S54107
Jokar M, Mirfeizi Z, Esmaili HMK (2016) Effect of vitamin K and alendronate combination treatment on bone mineral density of postmenopausal osteoporosis patients: a pilot study. Patient Saf Qual Improv 4(1):320–333. https://doi.org/10.22038/psj.2016.6288
Retraction blues (2013) Nat Med 19(12):1547–1548. https://doi.org/10.1038/nm.3426
Kanellakis S, Moschonis G, Tenta R, Schaafsma A, van den Heuvel EG, Papaioannou N, Lyritis G, Manios Y (2012) Changes in parameters of bone metabolism in postmenopausal women following a 12-month intervention period using dairy products enriched with calcium, vitamin D, and phylloquinone (vitamin K(1)) or menaquinone-7 (vitamin K (2)): the Postmenopausal Health Study II. Calcif Tissue Int 90(4):251–262. https://doi.org/10.1007/s00223-012-9571-z
Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chida S, Shimada Y (2014) Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab 32(3):290–297. https://doi.org/10.1007/s00774-013-0490-5
Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E (2013) Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 24(9):2499–2507. https://doi.org/10.1007/s00198-013-2325-6
Knapen MH, Schurgers LJ, Vermeer C (2007) Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int 18(7):963–972. https://doi.org/10.1007/s00198-007-0337-9
Koitaya N, Sekiguchi M, Tousen Y, Nishide Y, Morita A, Yamauchi J, Gando Y, Miyachi M, Aoki M, Komatsu M, Watanabe F, Morishita K, Ishimi Y (2014) Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women. J Bone Miner Metab 32(2):142–150. https://doi.org/10.1007/s00774-013-0472-7
Moschonis G, Kanellakis S, Papaioannou N, Schaafsma A, Manios Y (2011) Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II. J Bone Miner Metab 29(4):501–506. https://doi.org/10.1007/s00774-010-0256-2
Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T, Ochi H (2001) Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol 35(4):543–545. https://doi.org/10.1016/s0168-8278(01)00133-7
O'Connor EM, Grealy G, McCarthy J, Desmond A, Craig O, Shanahan F, Cashman KD (2014) Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn’s disease. Br J Nutr 112(7):1163–1174. https://doi.org/10.1017/S0007114514001913
Ronn SH, Harslof T, Pedersen SB, Langdahl BL (2016) Vitamin K2 (menaquinone-7) prevents age-related deterioration of trabecular bone microarchitecture at the tibia in postmenopausal women. Eur J Endocrinol 175(6):541–549. https://doi.org/10.1530/EJE-16-0498
Purwosunu Y, Muharram RIA, Reksoprodjo S, Sekizawa A (2006) Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia. J Obstet Gynaecol Res 32(2):230–234. https://doi.org/10.1111/j.1447-0756.2006.00386.x
Sasaki N, Kusano E, Takahashi H, Ando Y, Yano K, Tsuda E, Asano Y (2005) Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 23(1):41–47. https://doi.org/10.1007/s00774-004-0539-6
Shiomi S, Nishiguchi S, Kubo S, Tamori A, Habu D, Takeda T, Ochi H (2002) Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 97(4):978–981. https://doi.org/10.1111/j.1572-0241.2002.05618.x
Shiraki M, Itabashi A (2009) Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study. J Bone Miner Metab 27(3):333–340. https://doi.org/10.1007/s00774-008-0034-6
Shiraki M, Shiraki Y, Aoki C, Miura M (2000) Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15(3):515–521. https://doi.org/10.1359/jbmr.2000.15.3.515
Somekawa Y, Chigughi M, Harada M, Ishibashi T (1999) Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by leuprolide. J Clin Endocrinol Metab 84(8):2700–2704. https://doi.org/10.1210/jcem.84.8.5920
Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2017) Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab 35(4):385–395. https://doi.org/10.1007/s00774-016-0768-5
Ushiroyama T, Ikeda A, Ueki M (2002) Effect of continuous combined therapy with vitamin K2 and vitamin D3 on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 41(3):211–221. https://doi.org/10.1016/s0378-5122(01)00275-4
Volpe SL, Leung MM, Giordano H (2008) Vitamin K supplementation does not significantly impact bone mineral density and biochemical markers of bone in pre- and perimenopausal women. Nutr Res 28(9):577–582. https://doi.org/10.1016/j.nutres.2008.06.006
Yuko M, Hitoshi S, Masao K, Hiromitsu F, Satoshi M, Takashi K, Yasuhiko K, Tatsuya A, Teruo H, Katsuhiko A, Yasuhiko T (2014) Poster session-PS3-036 risedronate combined with menatetrenone may prevent glucocorticoid-induced osteoporosis in patients with chronic glomerulonephritis. Nephrology 19:77–202. https://doi.org/10.1111/nep.12237
Holden RM, Booth SL, Day AG, Clase CM, Zimmerman D, Moist L, Shea MK, McCabe KM, Jamal SA, Tobe S, Weinstein J, Madhumathi R, Adams MA, Heyland DK (2015) Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis 2:17. https://doi.org/10.1186/s40697-015-0053-x
Hampson G (2015) Vitamin K as additive treatment in osteoporosis. https://ClinicalTrials.gov/show/NCT01232647
Genant HK, Li J, Wu CY, JA S (2000) Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom 3:281–290
Fukunaga M, Nakamura T, Shiraki M, Kuroda T, Ohta H, Hosoi T, Orimo H (2004) Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese women. J Bone Miner Metab 22(2):104–110. https://doi.org/10.1007/s00774-003-0457-z
Tai V, Leung W, Grey A, Reid IR, Bolland MJ (2015) Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ 351:h4183. https://doi.org/10.1136/bmj.h4183
Veronese N, Bano G, Bertozzo G, Granziera S, Solmi M, Manzato E, Sergi G, Cohen AT, Correll CU (2015) Vitamin K antagonists’ use and fracture risk: results from a systematic review and meta-analysis. J Thromb Haemost 13(9):1665–1675. https://doi.org/10.1111/jth.13052
Bach AU, Anderson SA, Foley AL, Williams EC, Suttie JW (1996) Assessment of vitamin K status in human subjects administered “minidose” warfarin. Am J Clin Nutr 64(6):894–902. https://doi.org/10.1093/ajcn/64.6.894
Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW (2015) Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int 26(3):1175–1186. https://doi.org/10.1007/s00198-014-2989-6
Su S, He N, Men P, Song C, Zhai S (2019) The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. https://doi.org/10.1007/s00198-019-04853-7
Newman P, Shearer MJ (2008) Metabolism and cell biology of vitamin K. Thromb Haemost 100(10):530–547. https://doi.org/10.1160/th08-03-0147
Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G (2017) Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int 28(5):1531–1542. https://doi.org/10.1007/s00198-017-3909-3
Shea MK, Booth SL (2016) Concepts and controversies in evaluating vitamin K status in population-based studies. Nutrients 8(1). https://doi.org/10.3390/nu8010008
Funding
There was no funding for this systematic review.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Additional information
Data
Data and R code are available at https://doi.org/10.6084/m9.figshare.7315040 and https://doi.org/10.6084/m9.figshare.7315064.v1.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mott, A., Bradley, T., Wright, K. et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int 30, 1543–1559 (2019). https://doi.org/10.1007/s00198-019-04949-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-019-04949-0